Chao Sun

Chao Sun

Auto-generated profile, based on publicly available information

Chao Sun

Center for Fatty Liver Disease, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Key Lab of Pediatric Gastroenterology and Nutrition, Shanghai, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in Ultrasonography
Verified
Journal Article
Open access
PDF file
YHYun-Lin Huang
Yun-Lin Huang
CSChao Sun
Chao Sun
YDYi Dong
Yi Dong
JCJuan Cheng
Juan Cheng
SWShi-Wen Wang
Shi-Wen Wang
Yi DongYi Dong
Yi Dong
Purpose: This study assessed the performance of the ultrasound-guided attenuation parameter (UGAP) in diagnosing and grading hepatic steatosis in patients with metabolic dysfunctionassociated steatotic liver disease (MASLD). Magnetic resonance imaging proton density fat fraction (MRI-PDFF) served as the reference standard.Methods: Patients with hepatic steatosis were enrolled in this prospective study and underwent UGAP measurements. MRI-PDFF values of ≥5%, ≥15%, and ≥25% were used as references for the diagnosis of steatosis grades ≥S1, ≥S2, and S3, respectively. Spearman correlation coefficients and area under the receiver operating characteristic curves (AUCs) were calculated.Results: Between July 2023 and June 2024, the study included 88 patients (median age, 40 years; interquartile range [IQR], 36 to 46 years), of whom 54.5% (48/88) were men and 45.5% (40/88) were women. Steatosis grades exhibited the following distribution: 22.7% (20/88) had S0, 50.0% (44/88) had S1, 21.6% (19/88) had S2, and 5.7% (5/88) had S3. The success rate for UGAP measurements was 100%. The median UGAP value was 0.74 dB/cm/MHz (IQR, 0.65 to 0.82 dB/ cm/MHz), and UGAP values were positively correlated with MRI-PDFF (r=0.77, P<0.001). The AUCs of UGAP for the diagnoses of ≥S1, ≥S2, and S3 steatosis were 0.91, 0.90, and 0.88, respectively. In the subgroup analysis, 98.4% (60/61) of patients had valid controlled attenuation parameter (CAP) values. UGAP measurements were positively correlated with CAP values (r=0.65, P<0.001).Conclusion: Using MRI-PDFF as the reference standard, UGAP demonstrates good diagnostic performance in the detection and grading of hepatic steatosis in patients with MASLD.


27 January 2026 in Journal of Medical Internet Research
Verified
Journal Article
Open access
CSChao Sun
Chao Sun
GCGuangyu Chen
Guangyu Chen
CSCuicui Shi
Cuicui Shi
HCHaixia Cao
Haixia Cao
RYRuixu Yang
Ruixu Yang
JFJian-Gao Fan
Jian-Gao Fan
Background: For patients with metabolic dysfunction–associated fatty liver disease (MAFLD), weight loss is advised but challenging in practice. In China, there is a pronounced shortage of tailored digital lifestyle interventions for this population. Objective: This study aimed to assess the effects of a WeChat mini-program-delivered lifestyle intervention on weight loss and hepatic steatosis among individuals with MAFLD who were overweight or obese. Methods: Adults who are overweight or obese and have clinically diagnosed MAFLD with transient elastography examination were enrolled in this prospective randomized controlled trial. Patients were randomly assigned to receive either WeChat mini-program management (intervention group) or standard care (control group) at a 1:1 ratio. The intervention was structured around the development and implementation of personalized diet and exercise plans, supplemented by guided exercise video courses and reinforced through continuous monitoring and informational support. Body weight and clinical parameters were assessed at baseline and then at 6 months. Results: A total of 89 patients met the inclusion criteria and were randomly assigned to the intervention group (n=45) or control group (n=44). Among the 89 patients with MAFLD, 60% (27/45) of them achieved a eight loss of ≥5%, and 24.4% (11/45) of them had a weight loss of ≥10% in the intervention group, which was greater than those in the control group (27/45 vs 7/44; relative risk [RR] 3.771, 95% CI 1.836‐7.748; P <.001; 11/45 vs 3/44, RR 3.585, 95% CI 1.072‐11.988; P =.02). Importantly, patients receiving the intervention were significantly more likely to achieve a ≥10% reduction or normalization of controlled attenuation parameter (CAP) than those in the control group (26/45 vs 14/44; RR 1.816, 95% CI 1.102‐2.992; P =.01). After adjusting for key baseline covariates, multivariate analysis confirmed the intervention’s positive effect on achieving a weight loss of ≥5% (OR [odds ratio] 8.380, 95% CI 2.886‐24.331; P <.001) of ≥10% (OR 4.612, 95% CI 1.138‐18.686; P =.03), as well as on CAP reduction of ≥10 % or normalization (OR 2.853, 95% CI 1.092‐7.456; P =.03). In parallel, the intervention group presented greater reductions in liver enzymes (alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transpeptidase) and metabolic parameters (fasting insulin, h emoglobin A 1c , and triglyceride) than the control group (all P <.05). According to the fibrosis assessment, only the FibroScan-aspartate aminotransferase score decreased more in the intervention group than in the control group (median difference −0.06, 95% CI −0.13 to −0.01; P =.02), as compared to other non-invasive indicators. Conclusions: Readily scalable in primary care and varied-resource settings, our WeChat mini-program-based intervention extends beyond weight loss to reduce hepatic steatosis and improve metabolic parameters, thereby addressing the critical gap in targeted MAFLD management in China with a low-cost model for high-burden populations. Nevertheless, larger future studies are needed to confirm these findings with greater precision and assess long-term sustainability.

13 October 2025 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
YHYunlin Huang
Yunlin Huang
XXXinliang Xu
Xinliang Xu
CSChao Sun
Chao Sun
YDYi Dong
Yi Dong
YQYijie Qiu
Yijie Qiu
Yi DongYi Dong
Yi Dong

1 January 2026 in Ultrasonography
Verified
Journal Article
Open access
PDF file
YHYunlin Huang
Yunlin Huang
CSChao Sun
Chao Sun
XXXinliang Xu
Xinliang Xu
YDYi Dong
Yi Dong
LWLi Wei
Li Wei
Yi DongYi Dong
Yi Dong
Purpose: This study was performed to evaluate the diagnostic performance of ultrasound-derived fat fraction (UDFF) for detecting hepatic steatosis in patients with steatotic liver disease (SLD), using liver biopsy and histopathology as the gold standard.Methods: In this prospective study, patients referred for evaluation of suspected SLD were enrolled. All patients underwent UDFF and controlled attenuation parameter (CAP) measurements. Histopathological findings were assessed using the steatosis-activity-fibrosis scoring system as the gold standard. Pearson or Spearman correlation analyses and multivariate linear regression were performed. Areas under the receiver operating characteristic curves (AUCs) were utilized to assess the diagnostic performance of UDFF and CAP in identifying hepatic steatosis. The DeLong test was used to compare AUCs. Results: From February 2023 to May 2025, 66 patients were included. The median body mass index was 24 kg/m2. UDFF was positively correlated with hepatic steatosis grade (r=0.66). Using UDFF thresholds of 9.5%, 14.5%, and 16.3% (determined by the Youden index), the AUCs for detecting steatosis grades ≥S1, ≥S2, and S3 were 0.82, 0.90, and 0.99, respectively. UDFF exhibited a significantly higher AUC than CAP for detecting steatosis grade S3 (P=0.037). UDFF was correlated with hepatic steatosis grade, activity grade, CAP, aspartate aminotransferase level, and albumin level (all P<0.05). Conclusion: UDFF demonstrated good diagnostic performance for assessing hepatic steatosis, using histopathology as the reference. UDFF may serve as a quantitative imaging approach to measure liver fat content in patients with SLD.

18 April 2025 in JMIR Preprints
Verified
Preprint
Open access
CSChao Sun
Chao Sun
GCGuangyu Chen
Guangyu Chen
CSCuicui Shi
Cuicui Shi
HCHaixia Cao
Haixia Cao
RYRuixu Yang
Ruixu Yang
JFJian-Gao Fan
Jian-Gao Fan
BACKGROUND Weight loss is the standard recommendation for patients with metabolic dysfunction-associated fatty liver disease (MAFLD), but its successful implementation is difficult in practice. Digital lifestyle interventions may provide an efficient and scalable solution to enhance patient self-management. OBJECTIVE This study aimed to assess the effects of a WeChat mini-program-delivered lifestyle intervention on weight loss and hepatic steatosis among overweight or obese individuals with MAFLD METHODS Overweight or obese adults with clinically diagnosed MAFLD with transient elastography examination were enrolled in this prospective randomized controlled trial. Patients were randomly assigned to receive either WeChat mini-program management (intervention group) or standard care (control group) at a 1:1 ratio. Body weight and clinical parameters were assessed at baseline and then at 6 months. RESULTS Among the 89 included MAFLD patients, 60.0% achieved ≥5% weight loss, and 24.4% had ≥10% weight loss in the intervention group, which were greater than those in the control group (P <0.05). Importantly, patients receiving the intervention were significantly more likely to achieve a ≥10% controlled attenuation parameter (CAP)reduction or CAP normalization than those in the control group were (57.8% vs. 31.8%, P <0.05). In parallel, the intervention group presented greater reductions in liver enzymes (ALT, AST, and GGT) and metabolic parameters (fasting insulin, HbA1c, TG, and HDL-C) than the control group (P <0.05). According to the fibrosis assessment, only the FibroScan-aspartate aminotransferase (FAST) score decreased more in the intervention group than in the control group (P 0.05). CONCLUSIONS Digital lifestyle coaching via a WeChat mini-program demonstrates efficacy in enhancing weight reduction, improving hepatic steatosis, and ameliorating metabolic disorders, offering novel perspectives regarding the practicality and therapeutic value of digital tools in managing MAFLD through behavioral interventions. CLINICALTRIAL Chinese Clinical Trial Registry ChiCTR2500100197; https://www.chictr.org.cn/